Conestoga Capital Advisors LLC Position in Ligand Pharmaceuticals INC (LGND) Has Raised by $6.49 Million

November 10, 2018 - By Winifred Garcia

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) LogoInvestors sentiment increased to 1.11 in 2018 Q2. Its up 0.05, from 1.06 in 2018Q1. It increased, as 16 investors sold LGND shares while 109 reduced holdings. 42 funds opened positions while 97 raised stakes. 22.99 million shares or 1.94% more from 22.56 million shares in 2018Q1 were reported. Castleark Mgmt accumulated 92,215 shares or 0.59% of the stock. Assetmark invested 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Royal Savings Bank Of Canada invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Elk Creek Ltd Limited Liability Company reported 85,083 shares or 0.97% of all its holdings. 9,661 were accumulated by Brown Advisory Incorporated. Mackay Shields Limited Liability Company has 0.01% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 7,213 shares. Gabelli Funds Ltd Llc holds 0.02% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 17,000 shares. Goldman Sachs Group Inc has invested 0.02% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Icon Advisers accumulated 40,559 shares or 0.64% of the stock. Gsa Ptnrs Limited Liability Partnership reported 7,462 shares. Fortaleza Asset Mgmt holds 995 shares or 1.67% of its portfolio. Susquehanna Intl Grp Inc Incorporated Limited Liability Partnership holds 64,968 shares or 0% of its portfolio. The Illinois-based Nuveen Asset Mgmt Limited Liability Corporation has invested 0.02% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Wealthtrust owns 300 shares or 0.03% of their US portfolio. Moreover, Bank & Trust Of America De has 0% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 105,714 shares.

Since May 15, 2018, it had 0 insider purchases, and 14 sales for $47.40 million activity. The insider LAMATTINA JOHN L sold $850,292. On Tuesday, September 4 the insider Sabba Stephen L sold $1.28 million. Korenberg Matthew E also sold $4.71 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, August 29. Shares for $3.06 million were sold by FOEHR MATTHEW W. Shares for $6.76M were sold by Aryeh Jason on Thursday, August 16. The insider Berkman Charles S sold 2,813 shares worth $705,181.

Conestoga Capital Advisors Llc increased its stake in Ligand Pharmaceuticals Inc (LGND) by 6.67% based on its latest 2018Q2 regulatory filing with the SEC. Conestoga Capital Advisors Llc bought 31,364 shares as the company’s stock rose 38.65% with the market. The institutional investor held 501,894 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $103.98 million, up from 470,530 at the end of the previous reported quarter. Conestoga Capital Advisors Llc who had been investing in Ligand Pharmaceuticals Inc for a number of months, seems to be bullish on the $3.35B market cap company. The stock decreased 7.36% or $12.6 during the last trading session, reaching $158.59. About 824,542 shares traded or 32.56% up from the average. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 86.03% since November 10, 2017 and is uptrending. It has outperformed by 70.41% the S&P500.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Seekingalpha.com which released: “Ligand Pharmaceuticals beats by $0.29, beats on revenue” on November 08, 2018, also Streetinsider.com with their article: “Keysight Technologies (KEYS) Set to Join S&P 500; Ligand Pharmaceuticals (LGND) to Join S&P MidCap 400; Marcus …” published on October 30, 2018, Nasdaq.com published: “Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript” on November 08, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Nasdaq.com and their article: “3 Top Biotech Stocks to Buy Right Now” published on October 30, 2018 as well as Seekingalpha.com‘s news article titled: “Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2018 Results – Earnings Call Transcript” with publication date: November 08, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Ligand Pharmaceuticals has $270 highest and $23000 lowest target. $254’s average target is 60.16% above currents $158.59 stock price. Ligand Pharmaceuticals had 5 analyst reports since June 21, 2018 according to SRatingsIntel. Roth Capital downgraded Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, August 8 to “Neutral” rating. H.C. Wainwright maintained the shares of LGND in report on Wednesday, September 19 with “Buy” rating. Craig Hallum maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, June 27 with “Buy” rating.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>